

# Biogel® PI Micro range

## Chemotherapy agent permeation



Tested for use with  
chemotherapy agents

Agent tested	CAS no. (active ingredient)	Concentration	Biogel PI Micro REF 485	Biogel PI Micro Indicator Underglove REF 489	Biogel PI Micro Indicator System REF 483
Bleomycin (Blenoxane)	9041-93-4	15 mg/ml	>240	>240	>240
Busulfan	55-98-1	6 mg/ml	>240	>240	>240
Carboplatin (Paraplatin)	41575-94-4	10 mg/ml	>240	>240	>240
Carmustine* (BCNU)	154-93-8	3.3 mg/ml	10	13.2	>240
Cisplatin	15663-27-1	1 mg/ml	>240	>240	>240
Cyclophosphamide (Cytoxan)	50-18-0	20 mg/ml	>240	>240	>240
Cytarabine	147-94-4	100 mg/ml	>240	>240	>240
Dacarbazine (DTIC)	4342-03-4	10 mg/ml	>240	>240	>240
Doxorubicin Hydrochloride	23214-92-8	2 mg/ml	>240	>240	>240
Ellence	56420-45-2	2 mg/ml	>240	>240	>240
Etoposide (Toposar)	33419-42-0	20 mg/ml	>240	>240	>240
Fludarabine	21679-14-1	25 mg/ml	>240	>240	>240
Fluorouracil	51-21-8	50 mg/ml	>240	>240	>240
Idarubicin	57852-57-0	1 mg/ml	>240	>240	>240
Ifosfamide	3778-73-2	50 mg/ml	>240	>240	>240
Irinotecan	100286-90-6	20 mg/ml	>240	not tested	>240
Mechlorethamine HCl	55-86-7	1 mg/ml	>240	>240	>240
Melphalan	148-82-3	5 mg/ml	>240	>240	>240
Methotrexate	59-05-2	25 mg/ml	>240	>240	>240
Mitomycin C	50-07-7	0.5 mg/ml	>240	>240	>240
Mitoxantrone	70476-82-3	2 mg/ml	>240	>240	>240
Oxaliplatin	63121-00-6	2 mg/ml	>240	not tested	not tested
Paclitaxel (Taxol)	33069-62-4	6 mg/ml	>240	>240	>240
Rituximab	174722-31-7	10 mg/ml	>240	>240	>240
Thiotepa*	52-24-4	10 mg/ml	20.3	22.3	>240
Vincristine Sulfate	57-22-7	1 mg/ml	>240	>240	>240

### Test Results Based on ASTM D6978-05 Test Method Breakthrough detection time in minutes (0.01 µg/cm²/minutes)

**Note:** The Biogel® PI Micro, Biogel® PI Micro Indicator® Underglove and Biogel® PI Micro Indicator® System surgical gloves are intended to be worn on the hands, usually in the surgical settings, to provide barrier against potentially infectious material and other contaminants.

In addition, these gloves were tested at an independent test facility for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs.

Breakthrough detection times may not reflect the actual duration of protection in the workplace due to other factors influencing the performance, such as temperature, abrasion, puncture, degradation etc.

Gloves used for protection against chemotherapy drug exposure should be selected specifically for the types of chemical used. Users should review this information with information provided with the drug e.g. drug labeling or material safety data sheets for the chemicals being used to determine an adequate level of protection for the intended use.

**\*Warning:** Do not use single gloves for protection against Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml). Consider using additional safety controls when handling these materials to avoid contact as well as the use of multiple gloves with longer breakthrough detection times.

Performance level, breakthrough detection time

>240	121-240	61-120	31-60	11-30	≤10	not tested
------	---------	--------	-------	-------	-----	------------

All times are in minutes

Find out more at [molnlycke.com](https://molnlycke.com)

Mölnlycke Health Care AB, P.O. Box 13080, Gamlestadsvägen 3 C, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00. The Mölnlycke, Biogel and Indicator trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care group of companies.  
©2024 Mölnlycke Health Care AB. All rights reserved. HQIM006124

